Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Khan SA, Naz A, Qamar Masood M, Shah R
The American journal of cardiology · 61 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2020-08-15 · Am J Cardiol · vol. 134 · págs. 69–73
- Editorial
- Elsevier BV
- Citado
- 98 citas · más que el 97% de estudios similares · 4.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 22 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism · Lipid metabolism and disorders
- Palabras clave
- inclisiran, hypercholesterolemia, PCSK9 inhibitors, siRNA, LDL cholesterol lowering, major adverse cardiovascular events, apolipoprotein B, statin-resistant hypercholesterolemia, injection site reactions, lipid-lowering therapy
- MeSH
- humans, cardiovascular diseases, myocardial infarction, hypercholesterolemia, bilirubin, cholesterol, alkaline phosphatase, alanine transaminase, aspartate aminotransferases, creatine kinase, apolipoproteins b, rna, small interfering, anticholesteremic agents, hydroxymethylglutaryl-coa reductase inhibitors, drug therapy, combination, aged, middle aged, female, male, cholesterol, ldl, cholesterol, hdl, randomized controlled trials as topic, stroke, ezetimibe, injection site reaction
4 autores
- Sajjad Khan🇵🇰Aga Khan University
- Arshi Naz
- Muhammad Qamar Masood🇵🇰Aga Khan University
- Rahman Shah🇺🇸 · autor de correspondenciaAlabama College of Osteopathic Medicine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Statin therapy is the gold standard for hypercholesterolemia. However, a significant number of patients cannot achieve their target low-density lipoprotein (LDL) levels despite a maximal dose of statin therapy, and some cannot tolerate statins at all. Approval of proprotein convertase subtilisin/kexin type 9 inhibitors has been revolutionary for those patients. However, the need for frequent injections limits patient compliance with their use. Recently, a twice-yearly injection of inclisiran, a small interfering RNA, has been shown to inhibit hepatic synthesis of proprotein convertase subtilisin/kexin type 9. However, patient randomized clinical trial has been underpowered for clinical end points, necessitating a meta-analysis of those trials. The weighted mean difference was used to describe continuous variables, and pooled risk ratios, calculated using a random effects model, were used to describe discrete variables. Data from 3 randomized clinical trials comprising 3,660 patients showed that inclisiran decreased LDL cholesterol levels by 51% (95% Confidence Interval, 48 to 53%; p < 0.001) compared with placebo. It was associated with a 24% lower major adverse cardiovascular events rate (risk ratios = 0.76; 95% Confidence Interval, 0.61 to 0.92). It also significantly decreased total cholesterol by 37%, apolipoprotein B by 41%, and non high-density lipoprotein (HDL) cholesterol by 45% (all p < 0.001). No differences were found in adverse events, abnormalities in liver function tests, or creatine kinase levels between the treatment strategies. However, a mild injection site reaction occurred more frequently in the inclisiran group. In conclusions, in patients with hypercholesterolemia, inclisiran decreased LDL level by 51% without significant adverse effects. Additionally, it was associated with a lower major adverse cardiovascular event rate.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.